FindMyKOL
Clinical trialNCT03163667CompletedPhase 2Interventional

CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)

SponsorCalithera Biosciences, IncEnrollment69Clear Cell Renal Cell Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary objective of this study is to compare the progression-free survival (PFS) of participants treated with telaglenastat and everolimus versus placebo and everolimus for advanced or metastatic clear cell renal cell carcinoma (ccRCC) previously treated with the following: * At least 2 lines of therapy, including at least 1 vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) * Radiographic progression of metastatic RCC must have occurred (per investigator assessment) on or after the most recent systemic therapy and within 6 months prior to cycle 1 day 1
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

38 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • the University of Arizona Cancer Center

    Tucson, Arizona, United States

  • Highlands Oncology Group

    Rogers, Arkansas, United States

  • Los Angeles Hematology Oncology Medical Group

    Los Angeles, California, United States

  • Ucla Department of Medicine - Hematology/oncology

    Los Angeles, California, United States

  • Stanford Cancer Center

    Stanford, California, United States

  • Florida Cancer Specialists- South

    Fort Myers, Florida, United States

  • Florida Cancer Specialists- North

    St. Petersburg, Florida, United States

  • University Cancer & Blood Center, Llc

    Athens, Georgia, United States

  • Northwest Georgia Oncology Centers, P.C.

    Marietta, Georgia, United States

  • St. Luke'S Mountain States Tumor Institute

    Boise, Idaho, United States

  • Northwestern University

    Chicago, Illinois, United States

  • Parkview Research Center

    Fort Wayne, Indiana, United States

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa, United States

  • Norton Cancer Institute, Norton Healthcare Pavilion

    Louisville, Kentucky, United States

  • Ochsner Clinical Foundation

    New Orleans, Louisiana, United States

  • Anne Arundel Medical Center Oncology and Hematology

    Annapolis, Maryland, United States

  • University of Maryland, Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland, United States

  • Metro-Minnesota Community Oncology Research Consortium

    Saint Louis Park, Minnesota, United States

  • Mercy Clinic Oncology & Hematology

    Joplin, Missouri, United States

  • Scri Hca Midwest

    Kansas City, Missouri, United States

  • Washington University School of Medicine

    St Louis, Missouri, United States

  • St. Vincent Frontier Cancer Center

    Billings, Montana, United States

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada, United States

  • North Shore Hematology Oncology Associates Pc Dba Ny Cancer and Blood Specialists

    East Setauket, New York, United States

  • Nyu Winthrop Hospital - Cancer Clinical Trials Oncology/hematology

    Mineola, New York, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

  • Suny Upstate Medical University

    Syracuse, New York, United States

  • Montefiore Medical Center

    The Bronx, New York, United States

  • University of Cincinnati Medical Center

    Cincinnati, Ohio, United States

  • Ann B. Barshinger Cancer Institute / Lancaster General Hospital

    Lancaster, Pennsylvania, United States

  • Monongahela Valley Hospital

    Monongahela, Pennsylvania, United States

  • Charleston Hematology Oncology Associates,pa

    Charleston, South Carolina, United States

  • Ut/erlanger Oncology & Hematology

    Chattanooga, Tennessee, United States

  • Sarah Cannon Research Institute - Tennessee Oncology

    Nashville, Tennessee, United States

  • the University of Texas Md Anderson Cancer Center

    Houston, Texas, United States

  • Utah Cancer Specialists

    Salt Lake City, Utah, United States

  • Wenatchee Valley Hospital and Clinics

    Wenatchee, Washington, United States

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CB-839PlaceboEverolimus →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
6 Sept 2017
Primary completion
26 Apr 2019
Completion
1 Jun 2020
Last update posted
15 Sept 2022
Registered enrollment
69
Registry id
NCT03163667
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.